Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory Kounga teitei
Ko Shanghai Ruifu Chemical Co., Ltd. te kaihanga matua o Crizotinib (CAS: 877399-52-5) me te kounga teitei.Ka taea e Ruifu Chemical te tuku i te ao, te utu whakataetae, te ratonga pai, te iti me te rahinga e waatea ana.Hokona Crizotinib,Please contact: alvin@ruifuchem.com
| Ingoa matū | Crizotinib |
| Nga kupu taurite | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5-(1-Piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;(R)-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Tau CAS | 877399-52-5 |
| Tūnga Taonga | Kei roto i nga taonga, ka eke ki te rau kirokaramu |
| Tātai rāpoi | C21H22Cl2FN5O |
| Taumaha rāpoi | 450.34 |
| Iwi Whakarewa | 192℃ |
| Kiato | 1.47±0.10 g/cm3 |
| Paemahana Rokiroki | Te Pawera o te rūma |
| Taketake | Shanghai, Haina |
| Waitohu | Ruifu Chemical |
| Tūemi | Whakatakotoranga |
| Te ahua | Ma ki te Paura-White |
| Tautuhinga | Na IR, HPLC |
| Maramatanga o te Otinga | Kia rite ki te Paerewa |
| Ngaronga i te whakamaroke | ≤1.00% |
| Te toenga i runga i te mura | ≤0.50% |
| Nga poke e pa ana | (na HPLC) |
| Te poke kotahi | ≤0.50% |
| Nga poke katoa | ≤1.00% |
| Nga Korewa Taamaha | ≤20ppm |
| Te whakamatautau | ≥99.0% |
| Wairewa toenga | Tutaki ki te Whakatakotoranga |
| Te Ora Papa | 24 Marama |
| Paerewa Whakamatau | Paerewa hinonga |
Mōkī:Pounamu, Peeke konumohe konumohe, 25kg / Cardboard Drum, kia rite ranei ki te hiahia a te kaihoko.
Tikanga Rokiroki:Kia kati te ipu ka penapena ki roto i te whare putunga hauhautanga, maroke (2~8 ℃) me te hau pai kia matara atu i nga matū hotokore.Tiaki i te marama me te makuku.
Tukunga:Tukuna ki te ao ma te rangi, ma te FedEx / DHL Express.Whakaratohia te tuku tere me te pono.
Whakaahuatanga Haumaru 24/25 - Kaua e pa ki te kiri me nga kanohi.
UN ID UN 3077 9 / PGIII
WGK Tiamana 3
Waehere HS 2933990099
Ko te Roopu Whakamate
Ko te Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), he kaha me te whiriwhiri i te whakataetae ATP aukati iti o te ALK me te c-Met.I te marama o Akuhata 2011, i whakaaetia e te United States FDA a Crizotinib mo te maimoatanga o te anaplastic lymphoma kinase (ALK) kua whakarereketia te mate pukupuku pukupuku kore-iti-iti (NSCLC).Ko te Crizotinib he kaiwhakataetae whakataetae ATP takirua o te tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (pūtau IC50 = 8 nM) me te ALK (pūtau IC50 = 20 nM), he mea nui enei e rua mo te mate pukupuku mate pukupuku.I te wa i whakamatauria te crizotinib mo te whiriwhiringa me etahi atu kinase ka kitea he IC50 te enzyme i roto i nga taurea 100 o c-MET mo te 13 o nga kinase 120 i whakamatauria.I roto i nga whakamatautau waea, i kitea te crizotinib ki te whakakore i te RON (recepteur d'origine nantais) kinase me te matapihi whiriwhiringa 10-fold i runga i te c-MET.
Ko te Crizotinib (PF-02341066) Ko te Crizotinib he kaha c-Met me te aukati ALK, ko nga uara IC50 i roto i te whakamatautau pūtau he 11 nM me te 24 nM, ia.He aukati kaha o ROS1 me te uara Ki iti iho i te 0.025 nM.Ka taea e Crizotinib te whakakorikori i te autophagy i roto i te tini o nga raina pūtau mate pukupuku pūkahukahu ma te aukati i te ara STAT3.
Ko te Crizotinib he kaha me te whiriwhiri i te aukati rua o te mesenchymal-epithelial transition factor (c-MET) kinase me te anaplastic lymphoma kinase (ALK).Ko te Crizotinib he kaihoko antitumor pea.I te marama o Akuhata 2011, i whakaaetia e te United States FDA te crizotinib mo te maimoatanga o te anaplastic lymphoma kinase (ALK) kua whakarereketia te mate pukupuku pukupuku-kore-iti-iti (NSCLC).
Ko te Crizotinib (Xalkori(R), Pfizer), i whakaaetia i te tau 2011, ko te aukati tuatahi i whakaaetia e aro ana ki anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) o te tyrosine kinase insulin receptor class and MET proto-oncogene-encoded kinase o te hepatocyte growth factor receptor (HGFR) class are other kinases i arohia e crizotinib.I te wa i whakaaetia i te 2011, ko crizotinib te tuatahi te raau taero e aro ana ki nga turoro NSCLC.Heoi, ko te aukati ki te crizotinib i te nuinga o te wa ka kitea i roto i te 8 marama i muri i te tono tuatahi me te neke atu i te haurua o nga turoro i rongoahia e te crizotinib i pa ki nga paanga o te gastrointestinal.I te tau 2016, i whakaaetia ano a crizotinib mo te NSCLC pai-ROS1 e FDA.
Ko te Crizotinib (Xalkori) he kai-whakawa-waha tyrosine kinase aukati e tohuhia ana mo te maimoatanga o nga turoro me te mate pukupuku o te mate pukupuku o te puku kore-iti ranei (NSCLC).Ko nga paanga kino noa ki te whakamahi i te Xalkori ko te mate manawa o runga, te nausea, te ruaki, te mamae o te puku, te heke o te hiahia, te ohoroa, te mangere, te ngenge, te korere, te paopao, te ponana, te minamina ranei, nga tohu makariri (te ihu pupuhi, te tihe, te korokoro) te pupuhi, te pupuhi ranei i ou ringa, waewae ranei.
